We are live on ! Find out more
CYT

Cyteir Therapeutics, Inc. Common Stock
CYT

Delisted

CYT was delisted on the 15th of March, 2024.

Back to rankings

52 hedge funds and large institutions have $83.8M invested in Cyteir Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

8% more funds holding

Funds holding: 48 → 52 (+4)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

67% less capital invested

Capital invested by funds: $253M → $83.8M (-$170M)

Holders
52
Holders Change
+4
Holders Change %
+8.33%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
21
Reduced
9
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.57M
2
EWM
Evercore Wealth Management
New York
+$835K
3
BlackRock
BlackRock
New York
+$696K
4
Millennium Management
Millennium Management
New York
+$588K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$501K

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$4.46M
2
ABG
Ally Bridge Group
New York
-$3.63M
3
CCM
CAAS Capital Management
New York
-$2.12M
4
SI
Sofinnova Investments
California
-$2.04M
5
SFM
Sphera Funds Management
Israel
-$1.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$69K +$105K +18,393 New
ACM
27
ACT Capital Management
Pennsylvania
$57K – – –
Goldman Sachs
28
Goldman Sachs
New York
$52K +$9.45K +1,660 +14%
JP Morgan Chase
29
JP Morgan Chase
New York
$49K +$37.7K +6,616 +105%
N
30
Nuveen
North Carolina
$48K – – –
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$47K +$71.5K +12,555 New
CSS
32
Cubist Systematic Strategies
Connecticut
$47K +$71.6K +12,573 New
CC
33
Centiva Capital
New York
$45K +$67.5K +11,856 New
AIG
34
American International Group
New York
$35K +$27.5K +4,830 +109%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$30K +$19K +3,342 +74%
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$23K +$40 +7 +0.1%
Deutsche Bank
37
Deutsche Bank
Germany
$17K -$3.45K -606 -12%
TRCT
38
Tower Research Capital (TRC)
New York
$17K +$13.5K +2,380 +109%
Wells Fargo
39
Wells Fargo
California
$13K -$4.98K -875 -20%
Barclays
40
Barclays
United Kingdom
$12K +$17.3K +3,034 New
Allspring Global Investments
41
Allspring Global Investments
North Carolina
$10K -$3.26K -573 -17%
SPIA
42
Steward Partners Investment Advisory
New York
$8K -$5.69K -1,000 -31%
Legal & General Group
43
Legal & General Group
United Kingdom
$8K +$7.63K +1,340 +171%
SO
44
STRS Ohio
Ohio
$7K – – –
Citigroup
45
Citigroup
New York
$6K -$9.47K -1,663 -53%
AB
46
Amalgamated Bank
New York
$5K +$7.01K +1,232 New
AF
47
Amalgamated Financial
New York
$5K +$7.01K +1,232 New
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$4K -$6K -1,054 -48%
AIP
49
Ameritas Investment Partners
Nebraska
$2K – – –
PHK
50
Point72 Hong Kong
Hong Kong
$1K +$1.31K +231 New
1
2
3

CYT Hedge Fund Activity: Q1 2022 in Review

52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q1 2022, worth a combined $83.8M — down 67% from $253M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CYT positions and 9 closed out — a net gain of 4 holders — while 21 added to existing stakes and 9 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $2.57M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $4.46M sold.

  • 52 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q1 2022, up from 48 in Q4 2021.
  • Funds reported $83.8M of Cyteir Therapeutics, Inc. Common Stock stock for Q1 2022, down 67% quarter-over-quarter.
  • 13 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q1 2022 and 9 closed out, a net change of +4 holders.
  • The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q1 2022 was Fidelity Investments, an estimated $2.57M added.
  • The largest Cyteir Therapeutics, Inc. Common Stock seller in Q1 2022 was Acuta Capital Partners, an estimated $4.46M sold.

Based on aggregated 13F filings for Q1 2022.